Skip to main content

Free Content Oral miltefosine for Indian post‐kala‐azar dermal leishmaniasis: a randomised trial

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library



Standard treatment of Indian post‐kala‐azar dermal leishmaniasis (PKDL) is unsatisfactory because to achieve therapeutic effectiveness, heroic courses of parenteral and toxic agents have to be administered. Our objective was to evaluate oral miltefosine for its potential to provide effective as well as tolerable treatment for this disease.

Open‐label, randomised, parallel‐group multicentric trial. Miltefosine, 100 mg/day to all but one patient, was administered for 12 weeks or 8 weeks, with a target of 18 patients in each treatment group. Key endpoints were tolerance during treatment and efficacy at 12 months of follow‐up.

The ITT and per‐protocol cure rates after 12 months of follow‐up for patients receiving 12 weeks of therapy were 78% (14 of 18 patients: 95% CI = 61–88%) and 93% (14 of 15 patients: 95% CI = 71–95%), respectively, after 12 months of follow‐up. The ITT and per‐protocol cure rates for patients receiving 8 weeks of therapy were 76% (13 of 17 patients: 95% CI = 53–90%) and 81% (13 of 16 patients: 95% CI = 57–93%), respectively. Gastrointestinal and other adverse events were rare.

This study suggests that oral miltefosine for 2–3 months can be considered a treatment of choice for Indian PKDL.

Language: French

Document Type: Research Article


Publication date: January 1, 2013

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more